These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

797 related articles for article (PubMed ID: 25220114)

  • 1. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis.
    Tauhid S; Neema M; Healy BC; Weiner HL; Bakshi R
    J Neurol Sci; 2014 Nov; 346(1-2):250-4. PubMed ID: 25220114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.
    Tauhid S; Chu R; Sasane R; Glanz BI; Neema M; Miller JR; Kim G; Signorovitch JE; Healy BC; Chitnis T; Weiner HL; Bakshi R
    J Neurol; 2015 Nov; 262(11):2425-32. PubMed ID: 26205635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale.
    Bakshi R; Neema M; Healy BC; Liptak Z; Betensky RA; Buckle GJ; Gauthier SA; Stankiewicz J; Meier D; Egorova S; Arora A; Guss ZD; Glanz B; Khoury SJ; Guttmann CR; Weiner HL
    Arch Neurol; 2008 Nov; 65(11):1449-53. PubMed ID: 19001162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI phenotypes in MS: Longitudinal changes and miRNA signatures.
    Hemond CC; Healy BC; Tauhid S; Mazzola MA; Quintana FJ; Gandhi R; Weiner HL; Bakshi R
    Neurol Neuroimmunol Neuroinflamm; 2019 Mar; 6(2):e530. PubMed ID: 30800720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A semiautomated measure of whole-brain atrophy in multiple sclerosis.
    Bermel RA; Sharma J; Tjoa CW; Puli SR; Bakshi R
    J Neurol Sci; 2003 Apr; 208(1-2):57-65. PubMed ID: 12639726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
    J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis.
    Dalton CM; Bodini B; Samson RS; Battaglini M; Fisniku LK; Thompson AJ; Ciccarelli O; Miller DH; Chard DT
    Mult Scler; 2012 Mar; 18(3):322-8. PubMed ID: 21878451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study.
    Ramasamy DP; Benedict RH; Cox JL; Fritz D; Abdelrahman N; Hussein S; Minagar A; Dwyer MG; Zivadinov R
    J Neurol Sci; 2009 Jul; 282(1-2):47-54. PubMed ID: 19201003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.
    Kim G; Tauhid S; Dupuy SL; Tummala S; Khalid F; Healy BC; Bakshi R
    J Neurol; 2016 Mar; 263(3):531-8. PubMed ID: 26754005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis: hyperintense lesions in the brain on nonenhanced T1-weighted MR images evidenced as areas of T1 shortening.
    Janardhan V; Suri S; Bakshi R
    Radiology; 2007 Sep; 244(3):823-31. PubMed ID: 17690319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
    Zivadinov R; Uxa L; Bratina A; Bosco A; Srinivasaraghavan B; Minagar A; Ukmar M; Benedetto Sy; Zorzon M
    Int Rev Neurobiol; 2007; 79():521-35. PubMed ID: 17531857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E; Lee JC; Nakamura K; Rudick RA
    Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
    Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z
    Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study.
    Bakshi R; Healy BC; Dupuy SL; Kirkish G; Khalid F; Gundel T; Asteggiano C; Yousuf F; Alexander A; Hauser SL; Weiner HL; Henry RG;
    J Neuroimaging; 2020 Mar; 30(2):212-218. PubMed ID: 31994814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study.
    Tedeschi G; Dinacci D; Comerci M; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Patti F; Morra VB; Servillo G; Orefice G; Paciello M; Prinster A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Brunetti A; Salemi G; D'Amelio M; Simone I; Salvatore M; Bonavita V; Alfano B
    Mult Scler; 2009 Feb; 15(2):204-11. PubMed ID: 18987104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
    AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R
    J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative diffusion weighted imaging measures in patients with multiple sclerosis.
    Tavazzi E; Dwyer MG; Weinstock-Guttman B; Lema J; Bastianello S; Bergamaschi R; Cosi V; Benedict RH; Munschauer FE; Zivadinov R
    Neuroimage; 2007 Jul; 36(3):746-54. PubMed ID: 17498974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
    Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
    Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (1)H-MRSI evidence for cortical gray matter pathology that is independent of cerebral white matter lesion load in patients with secondary progressive multiple sclerosis.
    Caramanos Z; DiMaio S; Narayanan S; Lapierre Y; Arnold DL
    J Neurol Sci; 2009 Jul; 282(1-2):72-9. PubMed ID: 19232641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.